ACADIA CFO logs RSU vesting and tax-driven stock sales

Q: What did ACADIA (ACAD) CFO Mark C. Schneyer do in this Form 4?

He reported RSU vesting and related share sales. Schneyer exercised restricted stock units into 14,316 common shares at $0.00 per share, then sold 7,385 shares in open-market transactions primarily to cover tax withholding obligations.

Q: How many ACADIA (ACAD) shares did the CFO sell and at what prices?

He sold 7,385 shares of common stock. The open-market sales occurred on March 25 and 26, 2026 at prices of about $21.47, $21.65, and $21.7174 per share, according to the reported transaction details.

Q: Were the ACADIA (ACAD) CFO’s stock sales discretionary or tax-related?

The filing describes the sales as mandatory and tax-related. A footnote explains the sales were made to cover withholding taxes and related items tied to restricted stock unit vesting and are intended to comply with Rule 10b5-1 requirements.

Q: How many ACADIA (ACAD) shares does the CFO hold after these transactions?

He directly holds 60,269 common shares after the trades. The Form 4 shows this post-transaction balance following the RSU conversions and the sale of 7,385 shares executed in connection with tax obligations.

Q: What restricted stock unit activity did ACADIA (ACAD) disclose for its CFO?

Restricted stock units were converted into common shares. On March 24 and 25, 2026, 8,138 and 6,178 restricted stock units, respectively, were exercised at a conversion price of $0.00, each unit representing one share of common stock.

Q: How do the ACADIA (ACAD) CFO’s RSUs vest over time?

The RSUs vest in equal annual installments. One RSU grant vests in four equal yearly installments beginning March 24, 2026, and another vests in four equal yearly installments beginning March 25, 2025, as described in the footnotes.

ACADIA PHARMACEUTICALS EVP and CFO Mark C. Schneyer reported a combination of equity vesting and related share sales.

Filing Impact

(High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS EVP and CFO Mark C. Schneyer reported a combination of equity vesting and related share sales. On March 24 and 25, 2026, he exercised restricted stock units into a total of 14,316 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings.

On March 25 and 26, 2026, he sold an aggregate 7,385 shares of common stock in open-market transactions at prices around $21.47–$21.72 per share. A footnote states these mandatory sales were made to cover withholding taxes and related items in connection with the RSU vesting and are intended to comply with Rule 10b5-1. Following these transactions, he directly holds 60,269 shares of common stock.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Schneyer Mark C.

Role EVP, CHIEF FINANCIAL OFFICER

Sold 7,385 shs ($159K)

Approx. gross sale proceeds $159K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	3,171	$21.65	$69K
Sale	Common Stock	37	$21.7174	$803.54
Exercise	Restricted Stock Units	6,178	$0.00	$0.00
Sale	Common Stock	4,177	$21.47	$90K
Exercise	Common Stock	6,178	$0.00	$0.00
Exercise	Restricted Stock Units	8,138	$0.00	$0.00
Exercise	Common Stock	8,138	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 36,772 contracts (Direct); Common Stock — 60,269 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F3. The restricted stock units vest in four equal annual installments beginning March 24, 2026.
F4. The restricted stock units vest in four equal annual installments beginning March 25, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ACADIA (ACAD) CFO Mark C. Schneyer do in this Form 4?

He reported RSU vesting and related share sales. Schneyer exercised restricted stock units into 14,316 common shares at $0.00 per share, then sold 7,385 shares in open-market transactions primarily to cover tax withholding obligations.

How many ACADIA (ACAD) shares did the CFO sell and at what prices?

He sold 7,385 shares of common stock. The open-market sales occurred on March 25 and 26, 2026 at prices of about $21.47, $21.65, and $21.7174 per share, according to the reported transaction details.

How many ACADIA (ACAD) shares does the CFO hold after these transactions?

He directly holds 60,269 common shares after the trades. The Form 4 shows this post-transaction balance following the RSU conversions and the sale of 7,385 shares executed in connection with tax obligations.

What restricted stock unit activity did ACADIA (ACAD) disclose for its CFO?

Restricted stock units were converted into common shares. On March 24 and 25, 2026, 8,138 and 6,178 restricted stock units, respectively, were exercised at a conversion price of $0.00, each unit representing one share of common stock.

How do the ACADIA (ACAD) CFO’s RSUs vest over time?

The RSUs vest in equal annual installments. One RSU grant vests in four equal yearly installments beginning March 24, 2026, and another vests in four equal yearly installments beginning March 25, 2025, as described in the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/26/2026 - 08:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schneyer Mark C.

(Last)

(First)

(Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/24/2026		M		8,138	A	⁽¹⁾	61,476	D
Common Stock	03/25/2026		S⁽²⁾		4,177	D	$21.47	57,299	D
Common Stock	03/25/2026		M		6,178	A	⁽¹⁾	63,477	D
Common Stock	03/26/2026		S⁽²⁾		3,171	D	$21.65	60,306	D
Common Stock	03/26/2026		S⁽²⁾		37	D	$21.7174	60,269	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/24/2026		M			8,138	⁽³⁾	⁽³⁾	Common Stock	8,138	$0	24,414	D
Restricted Stock Units	⁽¹⁾	03/25/2026		M			6,178	⁽⁴⁾	⁽⁴⁾	Common Stock	6,178	$0	12,358	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

3. The restricted stock units vest in four equal annual installments beginning March 24, 2026.

4. The restricted stock units vest in four equal annual installments beginning March 25, 2025.

	/s/ Jennifer J. Rhodes, Attorney-in-Fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR